Versartis, Inc.
contact us
  • home
  • about us
  • leadership
  • technology
  • product pipeline
  • partners and licensing
  • news and events
 
  • Overview
  • VRS-859
  • AMX-808
  • VRS-826
  • VRS-317

Pipeline

VRS-826

Therapeutic Protein/Peptide Component:

 

Indication(s): 
Interleukin-1 receptor antagonist   Type 2 diabetes, rheumatoid arthritis
     

Development Status:

    
Preclinical    

 

 

  
     
Copyright © 2010 Versartis, Inc.